1. Avants, S. K., Margolin, A., Usubiaga, M. H., and Doebrick, C. (2004). Targeting HIV-related outcomes with intravenous drug users maintained on methadone: A randomized clinical trial of a harm reduction group therapy. Journal of Substance Abuse Treatment 26(2), pp. 67–78.
2. Ball, A., Des Jarlais, D. C., Donoghoe, M., Friedman, S. R., Goldberg, D., Hunter, G. M., Stimson, G. V., and Wodak, A. (1994). Multi-Centre Study on Drug Injecting and Risk of HIV Infection: Geneva: World Health Organization, Programme on Substance Abuse.
3. Blix, O. and Gronbladh, L. (1988). AIDS and IV Heroin Addicts: The Preventive Effect of Methadone Maintenance in Sweden. Paper presented at the Fourth International Conference on AIDS, Stockholm, Sweden.
4. Bluthenthal, R., Kral, A., Lorvick, J., Erringer, E., and Edlin, B. (1998). Harm reduction and needle exchange programs. Lancet 351(9118), pp. 1819–1820.
5. Bluthenthal, R., Kral, A., Gee, L., Lorvick, J., Moore, L., Srol, K., and Edlin, B. (2001). Trends in HIV seroprevalence and risk among gay or bisexual men who inject drugs in San Francisco, 1998 to 2000. Journal of Acquired Immune Deficiency Syndrome 14, pp. 264–269.